News

News

Date Title and Summary Additional Formats
Toggle Summary Ardelyx to Present at the Jefferies 2020 Virtual Healthcare Conference
FREMONT, Calif. , May 26, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that Mike Raab , president and
View HTML
Toggle Summary Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FREMONT, Calif. , May 21, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that on  May 18, 2020 , the
View HTML
Toggle Summary Ardelyx Strengthens Management Team with Appointment of Susan Rodriguez as Chief Commercial Officer
FREMONT, Calif. , May 18, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced the appointment of Susan Rodriguez
View HTML
Toggle Summary Ardelyx Reports First Quarter 2020 Financial Results and Recent Business Highlights
Company maintains strong balance sheet with $223.2 million in cash, cash equivalents and short-term investments FREMONT, Calif. , May 7, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve
View HTML
Toggle Summary Ardelyx Appoints Onaiza Cadoret-Manier to its Board of Directors
FREMONT, Calif. , March 16, 2020 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that Onaiza Cadoret-Manier , an industry
View HTML
Toggle Summary Ardelyx Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights
FREMONT, Calif. , March 6, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with cardiorenal diseases, today reported business highlights and financial results for the
View HTML
Toggle Summary Ardelyx to Present at the Cowen and Company 40th Annual Health Care Conference
FREMONT, Calif , Feb. 26, 2020 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab , president and chief executive officer of Ardelyx , will present at the Cowen and Company 40th Annual Health Care Conference at 8:00 a.m. ET on Wednesday, March 4, 2020 in Boston, MA.
View HTML
Toggle Summary Ardelyx to Present at the 9th Annual SVB Leerink Global Healthcare Conference
FREMONT, Calif. , Feb. 19, 2020 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab , president and chief executive officer of Ardelyx , will present at the 9 th Annual SVB Leerink Global Healthcare Conference at 3:30 p.m. ET on Wednesday, Feb. 26, 2020 in New York City .
View HTML
Toggle Summary Ardelyx Announces Pricing of Upsized Public Offering of Common Stock
FREMONT, Calif. , Dec. 4, 2019 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced the pricing of an underwritten public offering
View HTML
Toggle Summary Ardelyx Announces Proposed Public Offering of Common Stock
FREMONT, Calif. , Dec. 4, 2019 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that it has commenced an underwritten public
View HTML